Abstract |
Community-acquired pneumonia (CAP) is a common respiratory illness, frequently caused by Streptococcus pneumoniae. The prevalence of S. pneumoniae resistance to common antimicrobials has increased over recent years. A new pharmacokinetically enhanced formulation of amoxicillin/ clavulanate (2000/125 mg) has been developed, designed to combat infections caused by S. pneumoniae, including penicillin-resistant (PRSP, penicillin minimum inhibitory concentrations (MICs) >or=2mg/l) isolates, and those with elevated amoxicillin/clavulanic acid MICs, while maintaining coverage of beta-lactamase-producing pathogens. A pooled efficacy analysis of four randomized (1:1) and one non-comparative clinical trials of amoxicillin/ clavulanate, 2000/125 mg, given twice daily, was conducted in adult patients with CAP. Comparator agents were conventional amoxicillin/ clavulanate formulations. At follow-up (days 16-39), efficacy (eradication of the initial pathogen or clinical cure in patients for whom no repeat culture was performed) in patients with S. pneumoniae infection was 92.3% (274/297) for amoxicillin/ clavulanate, 2000/125 mg and 85.2% (46/54) for comparators (P=0.11). Twenty-four of 25 PRSP-infected patients receiving amoxicillin/ clavulanate, 2000/125 mg were treated successfully. Both amoxicillin/ clavulanate, 2000/125 mg and comparators were well tolerated, with few patients withdrawing from the studies.
|
Authors | Thomas M File, Javier Garau, Michael R Jacobs, Brian Wynne, Monique Twynholm, Elchonon Berkowitz |
Journal | International journal of antimicrobial agents
(Int J Antimicrob Agents)
Vol. 25
Issue 2
Pg. 110-9
(Feb 2005)
ISSN: 0924-8579 [Print] Netherlands |
PMID | 15664480
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Bacterial Agents
- Amoxicillin-Potassium Clavulanate Combination
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Amoxicillin-Potassium Clavulanate Combination
(pharmacokinetics, pharmacology, therapeutic use)
- Anti-Bacterial Agents
(pharmacokinetics, pharmacology, therapeutic use)
- Community-Acquired Infections
(drug therapy, microbiology)
- Double-Blind Method
- Drug Resistance, Bacterial
- Female
- Humans
- Male
- Middle Aged
- Penicillin Resistance
- Pneumonia, Pneumococcal
(drug therapy, microbiology)
- Streptococcus pneumoniae
(drug effects)
- Treatment Outcome
|